State Board of Administration of Florida Retirement System bought a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 28,563 shares of the company’s stock, valued at approximately $186,000.
Several other institutional investors and hedge funds also recently modified their holdings of LYEL. Nisa Investment Advisors LLC purchased a new stake in shares of Lyell Immunopharma in the second quarter worth about $38,000. Royal Bank of Canada boosted its position in shares of Lyell Immunopharma by 76.1% in the first quarter. Royal Bank of Canada now owns 9,114 shares of the company’s stock worth $46,000 after buying an additional 3,940 shares during the period. Metropolitan Life Insurance Co NY purchased a new position in Lyell Immunopharma in the first quarter valued at about $50,000. Dynamic Technology Lab Private Ltd purchased a new position in Lyell Immunopharma in the first quarter valued at about $52,000. Finally, Prudential Financial Inc. purchased a new position in Lyell Immunopharma in the first quarter valued at about $55,000. Hedge funds and other institutional investors own 40.25% of the company’s stock.
Lyell Immunopharma Stock Down 0.9 %
NASDAQ:LYEL opened at $4.28 on Wednesday. The business’s 50 day moving average is $6.36 and its two-hundred day moving average is $6.06. Lyell Immunopharma, Inc. has a 52 week low of $3.57 and a 52 week high of $10.33. The company has a market cap of $1.07 billion, a PE ratio of -4.81 and a beta of -2.01.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the company. The Goldman Sachs Group downgraded Lyell Immunopharma from a “buy” rating to a “neutral” rating and reduced their price target for the company from $13.00 to $7.00 in a report on Friday, November 11th. Morgan Stanley downgraded Lyell Immunopharma from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $15.00 to $7.00 in a report on Monday, November 14th. Finally, HC Wainwright reduced their price target on Lyell Immunopharma from $12.00 to $11.00 in a report on Wednesday, November 9th.
Insiders Place Their Bets
In other Lyell Immunopharma news, Director Richard Klausner sold 11,100 shares of the stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $6.40, for a total transaction of $71,040.00. Following the transaction, the director now owns 988,900 shares of the company’s stock, valued at approximately $6,328,960. The transaction was disclosed in a document filed with the SEC, which is available at this link. 25.80% of the stock is currently owned by company insiders.
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
- Get a free copy of the StockNews.com research report on Lyell Immunopharma (LYEL)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.